Altair Therapeutics Receives $17,000,000 New Financing Round

  • Feed Type
  • Date
    11/12/2009
  • Company Name
    Altair Therapeutics
  • Mailing Address
    12555 High Bluff Drive San Diego, CA 92130
  • Company Description
    Altair is building a dedicated team, combining antisense drug discovery expertise with respiratory drug development expertise, to focus solely on the development and commercialization of antisense drugs for the treatment of asthma and other respiratory conditions.
  • Website
    http://www.altairtherapeutics.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $17,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Altair Therapeutics will use the funding to complete phase 2a trials for its lead product, inhaled AIR645 and advance research and development in new target programs.
  • M&A Terms
  • Venture Investor
    Domain Associates
  • Venture Investor
    Thomas, McNerny & Partners
  • Venture Investor
    Forward Ventures
  • Venture Investor
    Isis Pharmaceuticals
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.